Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 367-373

  Rozenfeld, Julio H K ^a   Silva, Sandriana R ^b   Ranéia, Priscila A ^b   Faquim Mauro, Eliana ^b   Carmona Ribeiro, Ana M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Bilayer fragments; CpG oligonucleotide; Dioctadecyldimethylammonium bromide; Dynamic light scattering; Enhanced Th1 response; Ovalbumin

Indexed keywords

BILAYER FRAGMENTS; CATIONIC LIPIDS; COLLOIDAL STABILITY; DIOCTADECYL DIMETHYLAMMONIUM BROMIDES; ENHANCED TH1 RESPONSE; IMMUNE RESPONSE; IMMUNOADJUVANTS; IN-VIVO; OVALBUMINS;

AMMONIUM COMPOUNDS; BROMINE COMPOUNDS; DYNAMIC LIGHT SCATTERING; IMMUNIZATION; MAMMALS; OLIGONUCLEOTIDES;

HYDROPHOBICITY;

CPG OLIGODEOXYNUCLEOTIDE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; OVALBUMIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FOOT PAD; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; LIPID BILAYER; MOUSE; NONHUMAN; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; SUPRAMOLECULAR CHEMISTRY; SWELLING; TH1 CELL; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; CATIONS; CELLS, CULTURED; CYTOKINES; DRUG CARRIERS; DRUG STABILITY; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; LIPID BILAYERS; LYMPH NODES; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PARTICLE SIZE; QUATERNARY AMMONIUM COMPOUNDS; SURFACE PROPERTIES;

EID: 84861687871     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.10.017     Document Type: Article

References (54)

1. J. Kurreck Antisense technologies. Improvement through novel chemical modifications Eur. J. Biochem. 270 2003 1628 1644
2. D.M. Dykxhoorn, and J. Lieberman Knocking down disease with siRNAs Cell 126 2006 231 235
3. E.R. Rayburn, and R. Zhang Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov. Today 13 2008 513 521
4. J. Kurreck Therapeutic Oligonucleotides first ed. 2008 RSC Cambridge
5. J. Zhou, and J.J. Rossi Aptamer-targeted cell-specific RNA interference Silence 1 2010
6. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
7. C.R. Dass Vehicles for oligonucleotide delivery to tumors J. Pharm. Pharmacol. 54 2002 3 27
8. C.R. Dass Cyclodextrins and oligonucleotide delivery to solid tumours J. Drug Target. 12 2004 1 9
9. M. Saminathan, T. Antony, A. Shirahata, L.H. Sigal, T. Thomas, and T.J. Thomas Ionic and structural specificity effects of natural and synthetic polyamines on the aggregation and resolubilization of single-, double-, and triple-stranded DNA Biochemistry 38 1999 3821 3830
10. O. Zelphati, and F.C. Szoka Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids Pharm. Res. 13 1996 1367 1372
11. F. Shi, N.V. Gounko, X. Wang, E. Ronken, and D. Hoekstra In situ entry of oligonucleotides into brain cells can occur through a nucleic acid channel Oligonucleotides 17 2007 122 133
12. K. Konopka, E. Pretzer, P.L. Felgner, and N. Duzgunes Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes Biochim. Biophys. Acta 1312 1996 186 196
13. I. Jaaskelainen, J. Monkkonen, and A. Urtti Oligonucleotide-cationic liposome interactions. A physicochemical study Biochim. Biophys. Acta 1195 1994 115 123
14. S.D. Laufer, and T. Restle Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems Curr. Pharm. Des. 14 2008 3637 3655
15. B. Yu, R.J. Lee, and L.J. Lee Microfluidic methods for production of liposomes Methods Enzymol. 465 2009 129 141
16. A. Schroeder, C.G. Levins, C. Cortez, R. Langer, and D.G. Anderson Lipid-based nanotherapeutics for siRNA delivery J. Intern. Med. 267 2010 9 21
17. S.Y. Wu, and N.A. McMillan Lipidic systems for in vivo siRNA delivery AAPS J. 11 2009 639 652
18. S.C. Semple, A. Akinc, J. Chen, and M.J. Hope Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28 2010 172 176
19. W. Li, and F.C. Szoka Lipid-based nanoparticles for nucleic acid delivery Pharm. Res. 24 2007 438 449
20. N. Maurer, K.F. Wong, H. Stark, L. Louie, D. McIntosh, T. Wong, P. Scherrer, S.C. Semple, and P.R. Cullis Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes Biophys. J. 80 2001 2310 2326
21. Y. Yamada, K. Kogure, Y. Nakamura, K. Inoue, H. Akita, F. Nagatsugi, S. Sasaki, T. Suhara, and H. Harashima Development of efficient packaging method of oligodeoxynucleotides by a condensed nanoparticle in lipid envelope structure Biol. Pharm. Bull. 28 2005 1939 1942
22. J.E. Podesta, and K. Kostarelos Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery Methods Enzymol. 464 2009 343 354
23. A.M. Carmona-Ribeiro Biomimetic nanoparticles: preparation, characterization and biomedical applications Int. J. Nanomedicine 5 2010 249 259
24. J.H.K. Rozenfeld, T.R. Oliveira, M.T. Lamy, and A.M. Carmona-Ribeiro Interaction of cationic bilayer fragments with a model oligonucleotide Biochim. Biophys. Acta 1808 2011 649 655
25. A.M. Krieg, A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 1995 546 549
26. J. Vollmer, and A.M. Krieg Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Adv. Drug Deliv. Rev. 61 2009 195 204
27. Y. Kuramoto, M. Nishikawa, K. Hyoudou, F. Yamashita, and M. Hashida Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex J. Control. Release 115 2006 226 233
28. C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh, G. Albert, M. Al-Adhami, D. Readett, A.M. Krieg, and C.G. Leichman Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer J. Clin. Oncol. 26 2008 3979 3986
29. S. Zimmermann, O. Egeter, S. Hausmann, G.B. Lipford, M. Röcken, H. Wagner, and K. Heeg Cutting edge: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis J. Immunol. 160 1998 3627 3630
30. M. Isogawa, M.D. Robek, Y. Furuichi, and F.V. Chisari Toll-like receptor signaling inhibits hepatitis B virus replication in vivo J. Virol. 79 2005 7269 7272
31. J.N. Kline, K. Kitagaki, T.R. Businga, and V.V. Jain Treatment of established asthma in a murine model using CpG oligodeoxynucleotides Am. J. Physiol. Lung Cell. Mol. Physiol. 283 2002 L170 L179
32. F.E.R. Simons, Y. Shikishima, G. Van Nest, J.J. Eiden, and K.T. HayGlass Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA J. Allergy Clin. Immunol. 113 2004 1144 1151
33. N. Lincopan, N.M. Espíndola, A.J. Vaz, M.H.B. Costa, E. Faquim-Mauro, and A.M. Carmona-Ribeiro Novel immunoadjuvants based on cationic lipid: preparation, characterization and activity in vivo Vaccine 27 2009 5760 5771
34. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
35. A.M. Carmona-Ribeiro, and H. Chaimovich Preparation and characterization of large dioctadecyldimethylammonium chloride liposomes and comparison with small sonicated vesicles Biochim. Biophys. Acta 733 1983 172 179
36. J. Fendler Surfactant vesicles as membrane mimetic agents - characterization and utilization Acc. Chem. Res. 13 1980 7 13
37. O. Schales, and S.S. Schales A simple and accurate method for the determination of chloride in biological fluids J. Biol. Chem. 140 1941 879 884
38. A.M. Carmona-Ribeiro Bilayer-forming synthetic lipids: drugs or carriers? Curr. Med. Chem. 10 2003 2425 2446
39. L.A. Hilgers, and H. Snippe DDA as an immunological adjuvant Res. Immunol. 143 1992 494 503
40. E.B. Lindblad Aluminium adjuvants - in retrospect and prospect Vaccine 22 2004 3658 3668
41. J.A. Beeley, S.M. Stevenson, and J.G. Beeley Polyacrylamide gel isoelectric focusing of proteins: determination of isoelectric points using an antimony electrode Biochim. Biophys. Acta 285 1972 293 300
42. H.W. Walker, and S.B. Grant Influence of surface charge and particle size on the stabilization of colloidal particles by model polyelectrolytes Colloids Surf. A 135 1998 123 133
43. T. Matsumoto, and J. Chiba Rheological and small-angle A-ray scattering investigations on the shape and ordered arrangement of native ovalbumin molecules in aqueous colloids J. Chem. Soc., Faraday Trans. 86 1990 2877 2882
44. L.R. Tsuruta, W. Quintilio, M.H.B. Costa, and A.M. Carmona-Ribeiro Interactions between cationic liposomes and an antigenic protein: the physical chemistry of the immunoadjuvant action J. Lipid Res. 38 1997 2003 2011
45. L.A. Carvalho, and A.M. Carmona-Ribeiro Interactions between cationic vesicles and serum proteins Langmuir 14 1998 6077 6081
46. K.S. Korsholm, E.M. Agger, C. Foged, D. Christensen, J. Dietrich, C.S. Andersen, C. Geisler, and P. Andersen The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes Immunology 121 2007 216 226
47. M. Henriksen-Lacey, V.W. Bramwell, D. Christensen, E.M. Agger, P. Andersen, and Y. Perrie Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen J. Control. Release 142 2010 180 186
48. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M.F. Bachmann Nanoparticles target distinct dendritic cell populations according to their size Eur. J. Immunol. 38 2008 1404 1413
49. A.M. Krieg Therapeutic potential of Toll-like receptor 9 activation Nat. Rev. Drug Discov. 5 2006 471 484
50. P. Nordly, K.S. Korsholm, E.A. Pedersen, T.S. Khilji, H. Franzyk, L. Jorgensen, H.M. Nielsen, E.M. Agger, and C. Foged Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo Eur. J. Pharm. Biopharm. 77 2011 89 98
51. K.S. Korsholm, R.V. Petersen, E.M. Agger, and P. Andersen T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection Immunology 129 2009 75 86
52. C. Foged, B. Brodin, S. Frokjaer, and A. Sundblad Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model Int. J. Pharm. 298 2005 315 322
53. A. Joseph, I. Louria-Hayon, A. Plis-Finarov, E. Zeira, Z. Zakay-Rones, E. Raz, T. Hayashi, K. Takabayashi, Y. Barenholz, and E. Kedar Liposomal immunostimulatory DNA sequence (ISS-ON): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines Vaccine 20 2002 3342 3354
54. L.A. Mitchell, A. Joseph, E. Kedar, Y. Barenholz, and E. Galun Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid Vaccine 24 2006 5300 5310